Our product use eye-tracking and video technology to map the visual fields of patients by monitoring their instinctive responses to moverment and light. Our instruments expand the testable population for perimetry to over 95% of patients irrespective of age of neurological capability.
i2eye Diagnostics Ltd is a wonderful example of how Scotland’s world-class academic base, strong public sector support agencies, highly organised angel investment community and committed entrepreneurial talent can come together to create a great company.
i2eye Diagnostics is a product of the Edinburgh BioQuarter company creation process. It was founded to commercialise a novel and highly innovative ophthalmic medical device invented by Professors Brian Fleck and Bob Minns at the Royal Hospital for Sick Children in Edinburgh and at Edinburgh University. The new device uses eyetracking to objectively map the visual fields patients of all ages, including those with some neurological disability.
The company secured seed-funding from Kelvin Capital in January 2012 and in the following ten months, with help from Scottish Enterprise and the High Growth Start-Up Unit, the founding team put in place an ISO13485 accredited quality system and developed the product from a proof or concept prototype to an approved medical device cleared to market in the US and Europe. i2eye closed a second funding round in December 2012 again led by Kelvin Capital with Old College Capital and the Scottish Enterprise Co-Investment fund also making substantial contributions. The company made its first sales in November 2012 and now has customers around the world.
In 2013 i2eye secured additional intellectual property from the Universities of Cambridge and York to further expand the capability of its products to map visual fields for those patients with more severe neurological impairment. i2eye's immediate focus is towards paediatric neuro-ophthalmology and the assessment and rehabilitation of traumatic brain injury (TBI).
i2eye Diagnostics was awarded “Best New Life Sciences Company in Scotland” in 2013 and is now transitioning to a niche market leader beyond the start-up phase with products available in the key regulated markets of Europe, the USA and Australia.
We foster a culture of technical excellence, total integrity and entrepreneurial drive.